Advances in Therapy

, 26:25 | Cite as

Testosterone treatment in elderly men

  • U. Srinivas-Shankar
  • D. Sharma


Testosterone has been used in testicular and hypothalamo-pituitary diseases since the 1940s. There is growing interest in the use of testosterone in aging men, and this has stimulated research into the benefits of male hormone replacement. Testosterone treatment of men with hypogonadism might have beneficial effects on body composition, muscle strength, sexual function, and cognition. There are several modes of administration of the male hormone, with injectable testosterone esters and implanted testosterone pellets being the mainstay of treatment until recently. These preparations are increasingly being replaced by transdermal patches, gels, and long-acting parenteral preparations. Testosterone patches and gels are ideally for elderly men. Treatment with the male hormone is relatively safe, if patients are selected appropriately and monitored carefully. The most important adverse effects are on the prostate. In this review, we briefly discuss the indications, contraindications, and benefits of testosterone treatment. Further, we list the adverse effects, advantages, and disadvantages of various testosterone preparations in elderly men.


benefits elderly men hypogonadism testosterone preparations 


  1. 1.
    Richmond EJ, Rogol AD. Male pubertal development and the role of androgen therapy. Nat Clin Pract Endocrinol Metab. 2007;3:338–344.PubMedCrossRefGoogle Scholar
  2. 2.
    Schubert M, Jockenhovel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J Endocrinol Invest. 2005;28:23–27.PubMedGoogle Scholar
  3. 3.
    Vermeulen A, Verdonck L. Studies on the binding of testosterone to human plasma. Steroids. 1968;11:609–635.PubMedCrossRefGoogle Scholar
  4. 4.
    Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58–68.PubMedGoogle Scholar
  5. 5.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–731.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 1983;56:113–120.PubMedGoogle Scholar
  7. 7.
    Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 1992;88:15–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in non-genomic androgen actions. Mol Endocrinol. 2002;16:2181–2187.PubMedCrossRefGoogle Scholar
  9. 9.
    Winters SJ, Clark BJ. Testosterone synthesis, transport and metabolism. In: Winters SJ, Clark BJ, eds. Androgens in Health and Disease; 2003:3–22.Google Scholar
  10. 10.
    Christiansen K. Behavioral correlates of testosterone. In: Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. Cambridge: Cambridge University Press; 2004:125–172.Google Scholar
  11. 11.
    Wheeler MJ, Barnes SC. The measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clin Endocrinol (Oxf). 2008;69:515–525.CrossRefGoogle Scholar
  12. 12.
    MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104:648–651.PubMedGoogle Scholar
  13. 13.
    Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–858.PubMedCrossRefGoogle Scholar
  14. 14.
    Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36:333–348.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang C, Nieschlag E, Swerdloff R, et al. ISA, IS-SAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. J Androl. 2009;30:1–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immuno-deficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81:4051–4058.PubMedCrossRefGoogle Scholar
  17. 17.
    Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358–4365.PubMedCrossRefGoogle Scholar
  18. 18.
    Katznelson L, Rosenthal DI, Rosol MS, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol. 1998;170:423–427.PubMedGoogle Scholar
  19. 19.
    Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647–2653.PubMedCrossRefGoogle Scholar
  20. 20.
    Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502–1510.PubMedCrossRefGoogle Scholar
  21. 21.
    Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092–1098.PubMedCrossRefGoogle Scholar
  23. 23.
    Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999;22:261–265.PubMedCrossRefGoogle Scholar
  24. 24.
    Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618–625.PubMedGoogle Scholar
  25. 25.
    Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288:2282–2292.PubMedCrossRefGoogle Scholar
  26. 26.
    Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647–1659.PubMedCrossRefGoogle Scholar
  27. 27.
    Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–E607.PubMedGoogle Scholar
  28. 28.
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:M266–M272.PubMedGoogle Scholar
  29. 29.
    Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med. 2004;98:906–913.PubMedCrossRefGoogle Scholar
  30. 30.
    Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:870–878.PubMedCrossRefGoogle Scholar
  31. 31.
    Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049–1057.PubMedCrossRefGoogle Scholar
  32. 32.
    Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–688.PubMedCrossRefGoogle Scholar
  33. 33.
    Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003;88:3167–3176.PubMedCrossRefGoogle Scholar
  34. 34.
    Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407–413.PubMedCrossRefGoogle Scholar
  35. 35.
    Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88:1478–1485.PubMedCrossRefGoogle Scholar
  36. 36.
    Sih R, Morley JE, Kaiser FE, Perry HM3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–1667.PubMedCrossRefGoogle Scholar
  37. 37.
    Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc. 2000;48:550–553.PubMedGoogle Scholar
  38. 38.
    Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003;88:3605–3613.PubMedCrossRefGoogle Scholar
  39. 39.
    Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2006;91:477–484.PubMedCrossRefGoogle Scholar
  40. 40.
    Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56:1991–1999.PubMedCrossRefGoogle Scholar
  41. 41.
    Nankin HR, Lin T, Osterman J. Chronic testosterone cypionate therapy in men with secondary impotence. Fertil Steril. 1986;46:300–307.PubMedGoogle Scholar
  42. 42.
    Benkert O, Witt W, Adam W, Leitz A. Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Arch Sex Behav. 1979;8:471–479.PubMedCrossRefGoogle Scholar
  43. 43.
    Schiavi RC, White D, Mandeli J, Levine AC. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav. 1997;26:231–241.PubMedCrossRefGoogle Scholar
  44. 44.
    Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6:94–99.PubMedCrossRefGoogle Scholar
  45. 45.
    Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med. 2005;2:559–564.PubMedCrossRefGoogle Scholar
  46. 46.
    Francis RM, Peacock M, Aaron JE, et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone. 1986;7:261–268.PubMedCrossRefGoogle Scholar
  47. 47.
    Berger C, Langsetmo L, Joseph L, et al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ. 2008;178:1660–1668.PubMedGoogle Scholar
  48. 48.
    Paller CJ, Shiels MS, Rohrmann S, et al. Relationship of sex steroid hormones with bone mineral density in a nationally-representative sample of men. Clin Endocrinol (Oxf). 2009;70:26–34.CrossRefGoogle Scholar
  49. 49.
    Leifke E, Wichers C, Gorenoi V, Lucke P, von zur Muhlen A, Brabant G. Low serum levels of testosterone in men with minimal traumatic hip fractures. Exp Clin Endocrinol Diabetes. 2005;113:208–213.PubMedCrossRefGoogle Scholar
  50. 50.
    Christmas C, O’Connor KG, Harman SM, et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol A Biol Sci Med Sci. 2002;57:M12–M18.PubMedGoogle Scholar
  51. 51.
    Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966–1972.PubMedCrossRefGoogle Scholar
  52. 52.
    Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578–3583.PubMedCrossRefGoogle Scholar
  53. 53.
    Pope HGJr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:105–111.PubMedCrossRefGoogle Scholar
  54. 54.
    Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male. 2003;6:13–17.PubMedCrossRefGoogle Scholar
  55. 55.
    Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64:2063–2068.PubMedCrossRefGoogle Scholar
  56. 56.
    Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh). 1975;79:366–374.Google Scholar
  57. 57.
    Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol. 2003;21:311–315.PubMedCrossRefGoogle Scholar
  58. 58.
    Bagchus WM, Mink CPA, Maris F, Houwing NS. Bioequivalence of Andriol and Andriol Testocaps. Aging Male. 2001;4:259.Google Scholar
  59. 59.
    Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol (Oxf). 1984;21:97–107.CrossRefGoogle Scholar
  60. 60.
    Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994;15:212–215.PubMedGoogle Scholar
  61. 61.
    Petry R, Rausch-Stroomann JG, Hienz HA, Senge T, Mauss J. Androgen treatment without inhibiting effect on hypophysis and male gonads. Biochemical and morphological studies after treatment with mesterolone. Acta Endocrinol (Copenh). 1968;59:497–507.Google Scholar
  62. 62.
    Aakvaag A, Stromme SB. The effect of mesterolone administration to normal men on the pituitarytesticular function. Acta Endocrinol (Copenh). 1974;77:380–386.Google Scholar
  63. 63.
    Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. Cambridge: Cambridge University Press; 2004:405–444.Google Scholar
  64. 64.
    Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987;7:230–236.PubMedCrossRefGoogle Scholar
  65. 65.
    Foss GL, Simpson SL. Oral methyltestosterone and jaundice. BMJ. 1959;34:259–263.Google Scholar
  66. 66.
    Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2005;8:56–58.PubMedCrossRefGoogle Scholar
  67. 67.
    Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol (Oxf). 2004;60:420–428.CrossRefGoogle Scholar
  68. 68.
    Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf). 1996;45:61–71.CrossRefGoogle Scholar
  69. 69.
    Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990;71:216–222.PubMedCrossRefGoogle Scholar
  70. 70.
    Harle L, Basaria S, Dobs AS. Nebido: a long- acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother. 2005;6:1751–1759.PubMedCrossRefGoogle Scholar
  71. 71.
    Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001;54:739–750.CrossRefGoogle Scholar
  72. 72.
    Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet. 1986;2:943–946.PubMedCrossRefGoogle Scholar
  73. 73.
    Bals-Pratsch M, Langer K, Place VA, Nieschlag E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh). 1988;118:7–13.Google Scholar
  74. 74.
    Testosterone undecanoate—oral therapy for male hypogonadism. Drug Ther Bull. 1985;23:7–8.Google Scholar
  75. 75.
    Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf). 1997;47:727–737.CrossRefGoogle Scholar
  76. 76.
    Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469–3478.PubMedCrossRefGoogle Scholar
  77. 77.
    Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85:964–969.PubMedCrossRefGoogle Scholar
  78. 78.
    Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839–2853.PubMedCrossRefGoogle Scholar
  79. 79.
    Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994;40:341–349.CrossRefGoogle Scholar
  80. 80.
    Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299–311.PubMedGoogle Scholar
  81. 81.
    Snyder PJ, Peachey H, Berlin JA, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med. 2001;111:255–260.PubMedCrossRefGoogle Scholar
  82. 82.
    Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:261–269.PubMedCrossRefGoogle Scholar
  83. 83.
    Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57:M460–M465.PubMedGoogle Scholar
  84. 84.
    Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133:348–355.PubMedGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  1. 1.Department of Diabetes and EndocrinologyThe Royal Liverpool and Broadgreen University, Hospitals NHS TrustLiverpoolUK

Personalised recommendations